136.10
前日終値:
$134.71
開ける:
$134.69
24時間の取引高:
1.75M
Relative Volume:
0.76
時価総額:
$38.44B
収益:
$7.23B
当期純損益:
$1.41B
株価収益率:
27.33
EPS:
4.979
ネットキャッシュフロー:
$1.09B
1週間 パフォーマンス:
+1.88%
1か月 パフォーマンス:
+6.05%
6か月 パフォーマンス:
-2.54%
1年 パフォーマンス:
+19.99%
Agilent Technologies Inc Stock (A) Company Profile
名前
Agilent Technologies Inc
セクター
電話
(408) 345-8886
住所
5301 STEVENS CREEK BLVD, SANTA CLARA, CA
Compare A vs TMO, DHR, IDXX, NTRA
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
A
Agilent Technologies Inc
|
136.10 | 38.05B | 7.23B | 1.41B | 1.09B | 4.979 |
|
TMO
Thermo Fisher Scientific Inc
|
543.19 | 198.93B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
205.01 | 142.11B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
576.07 | 43.94B | 4.45B | 1.10B | 1.06B | 13.59 |
|
NTRA
Natera Inc
|
269.83 | 39.72B | 2.50B | -226.32M | 71.51M | -1.6412 |
Agilent Technologies Inc Stock (A) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-20 | 開始されました | HSBC Securities | Buy |
| 2026-01-05 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-12-15 | アップグレード | Barclays | Equal Weight → Overweight |
| 2025-12-09 | 開始されました | Goldman | Buy |
| 2025-12-02 | 開始されました | Morgan Stanley | Overweight |
| 2025-10-08 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-10-08 | アップグレード | UBS | Neutral → Buy |
| 2025-02-10 | アップグレード | Barclays | Underweight → Equal Weight |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-07-10 | アップグレード | Citigroup | Neutral → Buy |
| 2024-06-27 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2024-04-05 | アップグレード | Stifel | Hold → Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-12-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-11-17 | ダウングレード | UBS | Buy → Neutral |
| 2023-09-28 | 開始されました | Bernstein | Mkt Perform |
| 2023-07-31 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-05-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-24 | 繰り返されました | BofA Securities | Buy |
| 2023-05-24 | 繰り返されました | Citigroup | Neutral |
| 2023-05-24 | 繰り返されました | Credit Suisse | Outperform |
| 2023-05-24 | 繰り返されました | Evercore ISI | Outperform |
| 2023-05-24 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-24 | 繰り返されました | Robert W. Baird | Outperform |
| 2023-05-24 | 繰り返されました | SVB Securities | Outperform |
| 2023-05-24 | 繰り返されました | Stifel | Hold |
| 2023-05-24 | 繰り返されました | TD Cowen | Outperform |
| 2023-05-24 | 繰り返されました | Wells Fargo | Overweight |
| 2023-05-11 | 開始されました | Barclays | Equal Weight |
| 2023-01-10 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-07-20 | 開始されました | UBS | Buy |
| 2022-07-08 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-04-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-02-23 | 繰り返されました | BofA Securities | Buy |
| 2022-02-23 | 繰り返されました | Citigroup | Buy |
| 2022-02-23 | 繰り返されました | Cowen | Outperform |
| 2022-02-23 | 繰り返されました | Evercore ISI | Outperform |
| 2022-02-23 | 繰り返されました | Stifel | Hold |
| 2022-02-23 | 繰り返されました | Wells Fargo | Overweight |
| 2021-11-23 | 繰り返されました | BofA Securities | Buy |
| 2021-11-23 | 繰り返されました | Cowen | Outperform |
| 2021-11-23 | 繰り返されました | Stifel | Hold |
| 2021-03-18 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | アップグレード | BofA Securities | Neutral → Buy |
| 2020-12-02 | 開始されました | Goldman | Buy |
| 2020-11-25 | アップグレード | UBS | Neutral → Buy |
| 2020-11-17 | アップグレード | Cleveland Research | Neutral → Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2020-09-30 | 開始されました | Atlantic Equities | Neutral |
| 2020-08-19 | 繰り返されました | BofA Securities | Neutral |
| 2020-08-19 | 繰り返されました | Citigroup | Neutral |
| 2020-08-19 | 繰り返されました | Jefferies | Buy |
| 2020-08-19 | 繰り返されました | Robert W. Baird | Outperform |
| 2020-08-19 | 繰り返されました | SVB Leerink | Outperform |
| 2020-08-19 | 繰り返されました | Stifel | Hold |
| 2020-08-19 | 繰り返されました | Wells Fargo | Overweight |
| 2020-02-24 | ダウングレード | Needham | Buy → Hold |
| 2020-01-08 | 開始されました | Wells Fargo | Overweight |
| 2020-01-07 | 開始されました | Citigroup | Neutral |
| 2019-11-26 | 繰り返されました | Needham | Buy |
| 2019-11-15 | 開始されました | Stifel | Hold |
| 2019-10-18 | ダウングレード | UBS | Buy → Neutral |
| 2019-07-16 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-15 | ダウングレード | Barclays | Overweight → Equal Weight |
すべてを表示
Agilent Technologies Inc (A) 最新ニュース
Agilent Technologies Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
A4996671 Bond Profile — Key Metrics - TradingView
A5886204 Bond Profile — Key Metrics - TradingView
A5886359 Bond Profile — Key Metrics - TradingView
Agilent Technologies (NYSE:A) Nears A Technical Breakout - Kalkine Media
Agilent Technologies (NYSE:A) Shows Strong Breakout Setup with Top-Tier Technical Ratings - ChartMill
Agilent Technologies (A) Receives FDA Approval for New Diagnosti - GuruFocus
Oligonucleotide CDMO Market to Reach USD 9.87 Billion by 2031 as RNA-Targeted Drug Pipelines Expand - GlobeNewswire Inc.
Agilent Technologies (A) Receives FDA Approval for PD-L1 IHC 28-8 pharmDx Kit - GuruFocus
Agilent Technologies Receives Fda Approval for Pd-L1 Ihc 28-8 Pharmdx in Esophageal Squamous Cell Carcinoma, Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma - marketscreener.com
Agilent receives FDA approval for cancer diagnostic test - Investing.com
Agilent receives FDA approval for cancer diagnostic test By Investing.com - Investing.com Canada
Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma - Business Wire
A6433334 Bond Profile — Key Metrics - TradingView
Agilent expands Altura HPLC column portfolio for biopharma By Investing.com - Investing.com Nigeria
Agilent Technologies stock reflects steady diagnostics demand - Ad Hoc News
Agilent (A): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Baird Adjusts Agilent Technologies Price Target to $160 From $158, Maintains Outperform Rating - marketscreener.com
Agilent Technologies, Inc. (A) Stock Analysis: Is There a Potential 18.56% Upside for Investors? - DirectorsTalk Interviews
Is Agilent Technologies (A) A Bargain Following Its New Lab Tools And AI Software? - Sahm
Why Is Agilent (NYSE:A) Launching New AI Chromatography Tools? - Kalkine Media
Tangible book value per share of Agilent Technologies, Inc. – LSX:929138 - TradingView
Agilent rises on Q2 beats; adjusts fiscal 2026 guidance - MSN
Agilent Unveils the 9500 ICP-MS: Redefining Trace Element Analysis - AOL.com
Agilent (NYSE:A) Deepens Its AI Biopharma Push - Kalkine Media
Agilent Technologies stock stays supported by life-science demand - ad-hoc-news.de
Does Agilent (A) Signal a Deeper Shift With New AI Biopharma Tools and Columns? - simplywall.st
Agilent Technologies Inc (A) Stock Up 3.5% and Still Undervalued -- GF Score: 93/100 - GuruFocus
Agilent Technologies Inc. stock outperforms competitors on strong trading day - MarketWatch
Agilent Strengthens Biopharma Growth Prospects With AI Expansion - Yahoo Finance
AGILENT TECHNOLOGIES, INC. CMNRo Khanna Congressional Trade on Jun. 30, 2026 - Quiver Quantitative
Agilent expands Altura portfolio with inert size exclusion and PLRP-S columns for biotherapeutic analysis - BioSpectrum Asia
Agilent Technologies explores long-term growth drivers as a life sciences leader - ad-hoc-news.de
Jefferies resumes Agilent stock coverage with Hold rating By Investing.com - Investing.com South Africa
Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis - Business Wire
Jefferies resumes Agilent stock coverage with Hold rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Agilent Technologies Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Agilent Technologies earnings and business outlook. Investors focus on diagnostics and life sciences - ad-hoc-news.de
Agilent Expands HPLC Column Portfolio to Enhance Biotherapeutic Analysis - Contract Pharma
Agilent Technologies Inc. Expands Altura Portfolio with Inert Size Exclusion and Plrp-S Columns for Biotherapeutic Analysis - marketscreener.com
Is Agilent Technologies, Inc. (A) Stock Positioned for Growth as Life Sciences Sector Trends Stabilize? - Yahoo Finance
Agilent Slumps on Expansion Plans - TradingView
Agilent expands Altura HPLC column portfolio for biopharma - Investing.com
Agilent adds inert columns for tougher biopharma tests - Stock Titan
Agilent adds SEC and PLRP-S columns to Altura portfolio - StreetInsider
Agilent Technologies focuses on analytical solutions as investors watch long-term growth - ad-hoc-news.de
Agilent 1260 Infinity II LC from Agilent Technologiesworkhorse HPLC for busy US labs - ad-hoc-news.de
Agilent 6560 Ion Mobility LC/Q-TOF from Agilentniche lab workhorse gains quiet momentum - AD HOC NEWS
Agilent (A) Stock Looks Below Fair Value On Cash Flow - Yahoo Finance
Agilent Announces Cash Dividend of 25.5 Cents per Share - AOL.com
Agilent Technologies Inc (A) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):